Enjoy complimentary customisation on priority with our Enterprise License!
The degenerative disc disease market size is forecast to increase by USD 1.04 billion, at a CAGR of 8.51% between 2023 and 2028. The market is experiencing significant growth due to several key factors. The aging population, with an increasing prevalence of degenerative disc disease among older adults, is a major driver for market expansion. Additionally, the launch of innovative therapeutic approaches, such as minimally invasive surgeries and biologic therapies, is attracting a larger patient population. Conjoint analysis reveals that patients are increasingly seeking alternative therapies, including chiropractic care and physical therapy, to manage their symptoms before considering surgery. These trends are expected to continue, making the market a promising area for investment and innovation in the healthcare sector.
Degenerative disc disease (DDD) is a common spinal condition characterized by the degeneration of intervertebral discs, leading to back and neck pain. Two related conditions, spondylolisthesis and retrospondylolisthesis, also contribute to DDD symptoms. Lumbar spinal stenosis, another related condition, causes narrowing of the spinal canal, leading to pressure on the nerves and resulting in pain and disability. Biopharmaceutical companies are actively exploring various therapeutic approaches for DDD, including oral treatments such as peripherally acting analgesics and shock absorbers. Spinevision, a leading player in the spine industry, offers minimally invasive solutions for DDD, including disc/spine programs and metabolic programs.
Artificial disc replacement, a surgical intervention, is an alternative to spinal fusion for treating DDD in the cervical, lumbar, and thoracic spine. Hospitals and clinics are key end-users of these treatments, with Wakayama Medical University in Japan being a notable research center in this field. Conjoint analysis, a statistical method, is used to understand patient preferences and determine the optimal treatment combination for DDD. The patient population for DDD is large and growing, making it a significant market opportunity for therapeutic innovations.
The market research report provides comprehensive data (region-wise segment analysis), with forecasts and estimates in "USD Billion" for the period 2024-2028, as well as historical data from 2018-2022 for the following segments.
The drugs segment is estimated to witness significant growth during the forecast period. The global market for Degenerative Disc Disease (DDD), particularly focusing on the Lumbar and Thoracic Spine, is projected to expand significantly during the forecast period. Approximately 70% to 80% of adults under the age of 50 and over 90% of those over 60 have spinal disc degeneration. In its initial stages, DDD is typically managed with over-the-counter or prescription medications, including nonsteroidal anti-inflammatory drugs (NSAIDs). However, severe pain may necessitate more potent treatments, such as corticosteroid injections to alleviate inflammation and pain, neuropathic medications to address pain from compressed nerves, muscle relaxants to relieve muscle spasms, or opioids as a last resort.
Get a glance at the market share of various segments Request Free Sample
The drugs segment was valued at USD 1.03 billion in 2018 and showed a gradual increase during the forecast period.
North America is estimated to contribute 43% to the growth of the global market during the forecast period. Technavio's analysts have elaborately explained the regional trends and drivers that shape the market during the forecast period.
For more insights on the market share of various regions Request Free Sample
The North American region is anticipated to lead the market over the forecast period. Key drivers contributing to this growth include the expanding geriatric population, advanced technologies, frequent product launches, increasing awareness campaigns for early disease detection, and substantial healthcare expenditures. The United States and Canada are the primary contributors to the North American DDD market's revenue generation. In the United States, the market is projected to experience substantial growth due to the increasing elderly population and rising healthcare spending. Other factors, such as improved diagnostic techniques and the availability of advanced treatments like spinal fusion, further bolster the market's expansion in North America.
Our researchers analyzed the data with 2023 as the base year, along with the key drivers, trends, and challenges. A holistic analysis of drivers will help companies refine their marketing strategies to gain a competitive advantage.
The growing geriatric population is the key driver of the market. The aging population's increased susceptibility to degenerative disc disease (DDD) in the spine is driving significant demand for advanced diagnostic, assistance, maintenance, and treatment solutions within the healthcare industry. According to The World Bank Group, the global population aged 65 and above has grown from 8% to 10% of the total population between 2010 and 2020. This demographic shift has resulted in a heightened focus on addressing age-related degenerative changes affecting human intervertebral discs, which contribute to common issues such as spine stiffness, neck pain, and back pain in older adults.
The launch of innovative products is the upcoming trend in the market. The market witnesses ongoing innovation from key players, introducing advanced technologies to enhance treatment efficacy. In May 2020, DePuy Synthes unveiled their latest offering, the CONCORDE LIFT Interbody Implant, designed to streamline spinal fusion surgery for DDD patients. This device aims to restore spinal disc height by positioning a bone or bone-like material between two vertebrae. Spinal fusion surgery is a recognized procedure for treating DDD, and this new implant simplifies crucial stages of the process.
The availability of alternative therapies is a key challenge affecting the market growth. The market is witnessing growth due to the increasing prevalence of the condition and the development of advanced therapies. However, the availability of alternative treatment options, such as physiotherapy and specialized exercises, may hinder market expansion. According to research published in the Toronto Physiotherapy Journal in January 2014, physiotherapy is the preferred initial treatment for DDD in the elderly population. Standard care for suspected disc degeneration typically involves physiotherapy, although anti-inflammatory medications and epidural injections may also be used in more severe cases. As awareness about medication side effects grows, patients are increasingly opting for non-invasive therapies like physiotherapy.
The market forecasting report includes the adoption lifecycle of the market, covering from the innovator's stage to the laggard's stage. It focuses on adoption rates in different regions based on penetration. Furthermore, the report also includes key purchase criteria and drivers of price sensitivity to help companies evaluate and develop their market growth analysis strategies.
Customer Landscape
Companies are implementing various strategies, such as strategic alliances, partnerships, mergers and acquisitions, geographical expansion, and product/service launches, to enhance their presence in the market.
AnGes Inc - The company offers the treatment of degenerative disc disease through the use of its advanced activC Cervical Disc Prosthesis.
The market research and growth report includes detailed analyses of the competitive landscape of the market and information about key companies, including:
Qualitative and quantitative analysis of companies has been conducted to help clients understand the wider business environment as well as the strengths and weaknesses of key market players. Data is qualitatively analyzed to categorize companies as pure play, category-focused, industry-focused, and diversified; it is quantitatively analyzed to categorize companies as dominant, leading, strong, tentative, and weak.
The market represents a significant opportunity for biopharmaceutical companies to develop innovative therapeutic approaches for various spinal conditions, including spondylolisthesis, retrospondylolisthesis, and lumbar spinal stenosis. Oral treatments, such as peripherally acting analgesics, continue to dominate the market, offering pain relief for patients. However, the demand for advanced solutions, like artificial disc replacement and spinal fusion, is growing. Major players, such as Medtronic and Stryker, have strong disc/spine programs and metabolic programs to cater to the needs of hospitals and clinics. These companies focus on developing pipeline products, including shock absorbers and other innovative technologies, to address the unmet needs of the patient population.
Moreover, the current treatment practices for degenerative disc disease include surgical interventions, such as spinal fusion, and non-surgical options, like physical therapy and pain management. Conjoint analysis reveals that patient preferences for therapeutic approaches vary based on factors like age, severity of symptoms, and personal preferences. The cervical, lumbar, and thoracic spine are common areas affected by degenerative disc disease. Biopharmaceutical companies are focusing on developing treatments for all three regions to cater to the diverse needs of the patient population. The market is expected to grow significantly due to the increasing prevalence of these conditions and the unmet needs for effective, long-term solutions.
Further, at King's College Hospital London, the Department of Molecular Biosciences is advancing innovative oral treatments through specialized programs such as the Disc/Spine Program and the Metabolic Program. These initiatives focus on addressing conditions related to the cervical and lumbar spine, offering cutting-edge therapies that target spinal health. The Disc/Spine Program explores the underlying molecular mechanisms of disc degeneration and spine-related disorders, while the Metabolic Program investigates systemic factors impacting spinal health. With a commitment to research and development, the pipeline product profiles highlight promising advancements aimed at improving patient outcomes. By integrating molecular bioscience with clinical applications, the hospital is at the forefront of transformative spine care.
|
Market Scope |
|
|
Report Coverage |
Details |
|
Page number |
136 |
|
Base year |
2023 |
|
Historic period |
2018-2022 |
|
Forecast period |
2024-2028 |
|
Growth momentum & CAGR |
Accelerate at a CAGR of 8.51% |
|
Market Growth 2024-2028 |
USD 1.04 billion |
|
Market structure |
Fragmented |
|
YoY growth 2023-2024(%) |
7.66 |
|
Regional analysis |
North America, Europe, Asia, and Rest of World (ROW) |
|
Performing market contribution |
North America at 43% |
|
Key countries |
US, Germany, UK, China, and Japan |
|
Competitive landscape |
Leading Companies, Market Positioning of Companies, Competitive Strategies, and Industry Risks |
|
Key companies profiled |
AnGes Inc, Ankasa, B.Braun SE, BIOPHARM GmbH, BioRestorative Therapies Inc, BioSenic SA, Biosplice Therapeutics Inc., CalSpine MD, Cousin Biotech, DiscGenics Inc., Globus Medical Inc., Johnson and Johnson Services Inc., Medtronic Plc, Pfizer Inc., RTI Surgical Inc., Smith and Nephew plc, Ulrich Medical USA Inc., and Zimmer Biomet Holdings Inc. |
|
Market dynamics |
Parent market analysis, market growth inducers and obstacles, market forecast, fast-growing and slow-growing segment analysis, COVID-19 impact and recovery analysis and future consumer dynamics, market condition analysis for the forecast period |
|
Customization purview |
If our market report has not included the data that you are looking for, you can reach out to our analysts and get segments customized. |
We can help! Our analysts can customize this market research report to meet your requirements.
1 Executive Summary
2 Market Landscape
3 Market Sizing
4 Historic Market Size
5 Five Forces Analysis
6 Market Segmentation by Product
7 Customer Landscape
8 Geographic Landscape
9 Drivers, Challenges, and Opportunity/Restraints
10 Competitive Landscape
11 Competitive Analysis
12 Appendix
Get the report (PDF) sent to your email within minutes.
Get lifetime access to our
Technavio Insights
Quick Report Overview:
Cookie Policy
The Site uses cookies to record users' preferences in relation to the functionality of accessibility. We, our Affiliates, and our Vendors may store and access cookies on a device, and process personal data including unique identifiers sent by a device, to personalise content, tailor, and report on advertising and to analyse our traffic. By clicking “I’m fine with this”, you are allowing the use of these cookies. Please refer to the help guide of your browser for further information on cookies, including how to disable them. Review our Privacy & Cookie Notice.
